Gilliot S, et al. - This research was initiated in order to examine if the 3-month outcome of patients treated with intravenous (iv) recombinant tissue-plasminogen activator (rt-PA) for cerebral ischemia was affected by on-going therapy with angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs). On-going treatment with ACE-Is or ARBs did not exert any impact on the outcomes after adjustment on baseline characteristics and propensity scores in subjects treated who received intravenous thrombolytic therapy for ischemic stroke.